Antimicrobial Agents and Chemotherapy
- β-Lactamase diversity in Acinetobacter baumannii
- Cefepime–taniborbactam and ceftibuten–ledaborbactam maintain activity against KPC variants that lead to ceftazidime–avibactam resistanceby Cullen L. MyersAnnie StevensonBrittany MillerDenis M. DaigleTsuyoshi UeharaDaniel C. Pevear1Department of Molecular and Cellular Biology, University of Guelph317113, Guelph, Ontario, Canada2Venatorx Pharmaceuticals Inc.540451, Malvern, Pennsylvania, USARyan K. Shields on February 10, 2025 at 8:00 am
- Isolation and characterization of Plasmodium falciparum blood-stage persisters by improved selection protocols using dihydroartemisinin alone
- β-Lactamase diversity in Pseudomonas aeruginosa
- Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing
- Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime–avibactam in combination
- Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill patients
- Prediction of higher ceftazidime–avibactam concentrations in the human renal interstitium compared with unbound plasma using a minimal physiologically based pharmacokinetic model developed in rats and pigs through microdialysis
- Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants—a randomized, open-label, three-period, crossover study
- Guidelines vs mindlines: a qualitative investigation of how clinicians’ beliefs influence the application of rapid molecular diagnostics in intensive care
- Artemisinin pressure in field isolates can select highly resistant Plasmodium falciparum parasites with unconventional phenotype and no K13 mutation
- Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: a real-world 48-week extension study
- Double carbapenemases in Klebsiella pneumoniae blood isolates: dissemination in a single medical center via multiple plasmids and a variety of highly efficient clones
- Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants
- Assessing the threat of Yersinia pestis harboring a multi-resistant IncC plasmid and the efficacy of an antibiotic targeting LpxC
- Liposomal amphotericin B and complement activation-related pseudoallergy (CARPA)
- Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD
- Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030
- Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?
- Erratum for Xu et al., “Deoxyshikonin: a promising lead drug grass against drug resistance or sensitivity to Helicobacter pylori in an acidic environment”by Jia-yin XuHui-hua DongLi-juan LiaoShi-xian YangLu-yao WangHao ChenPeipei LuoLiang HuangAi-xing GuanYan-Qiang Huang on January 27, 2025 at 8:00 am